{
    "clinical_study": {
        "@rank": "51767", 
        "arm_group": {
            "arm_group_label": "Single Arm: RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, open-label, single arm long term extension of study WA19926 will evaluate\n      the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with early, moderate\n      to severe rheumatoid arthritis who have completed the WA19926 core study. Eligible patients\n      will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for up to 104 weeks."
        }, 
        "brief_title": "A Long-Term Extension Study to WA19926 of RoActemra/Actemra (Tocilizumab) in Patients With Early, Moderate to Severe Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients who complete WA19926 core study (visit at Week 104 and two follow-up\n             telephone visits) and who may benefit from study drug treatment according to the\n             Investigator's assessment\n\n          -  No current or recent adverse event or laboratory finding preventing the use of the\n             study drug dose of RoActemra/Actemra 8 mg/kg at baseline visit\n\n          -  Receiving treatment on an outpatient basis\n\n          -  Females of child-bearing potential must agree to use at least one adequate method of\n             contraception as defined by protocol during the treatment period\n\n        Exclusion Criteria:\n\n          -  Pregnant women\n\n          -  Patients who have prematurely withdrawn from the WA19926 study for any reason\n\n          -  Treatment with any investigational agent or cell depleting therapies since last\n             administration of study drug in the WA 19926 core study\n\n          -  Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL)1 agent,\n             or a T-cell costimulation modulator since the last administration of the study drug\n             in the WA19926 core study\n\n          -  Immunization with a live/attenuated vaccine since the last administration of study\n             drug in the WA19926 core study\n\n          -  Diagnosis since visit at Week 104 of the core WA19926 study of rheumatic autoimmune\n             disease other than rheumatoid arthritis\n\n          -  Diagnosis since visit at Week 104 of the core WA19926 study of inflammatory joint\n             disease other than rheumatoid arthritis\n\n          -  Evidence of serious uncontrolled concomitant disease or disorder\n\n          -  Known active or history of recurrent infection\n\n          -  Current liver disease as determined by Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01665430", 
            "org_study_id": "ML28175"
        }, 
        "intervention": {
            "arm_group_label": "Single Arm: RoActemra/Actemra", 
            "description": "8 mg/kg iv every 4 weeks, up to 104 weeks", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bytom", 
                        "country": "Poland", 
                        "zip": "41-902"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elblag", 
                        "country": "Poland", 
                        "zip": "82-300"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poznan", 
                        "country": "Poland", 
                        "zip": "60-218"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland", 
                        "zip": "02-637"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients From Poland With Early, Moderate to Severe Rheumatoid Arthritis.", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Poland: Ministry of Health"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Rates of adverse events leading to dose modification or study withdrawal", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Incidence of clinically significant laboratory abnormalities", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01665430"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Disease Activity Score 28 Erythrocyte sedimentation rate (DAS28-ESR)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 104"
            }, 
            {
                "measure": "Change in tender/swollen joint counts (TJC/SJC)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 104"
            }, 
            {
                "measure": "Proportion of patients achieving drug-free remission, defined as clinical remission (DAS28-ESR < 2.6) for two consecutive assessment visits followed by discontinuation of RoActemra/Actemra", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Time to rheumatoid arthritis flare in patients who have entered drug-free remission", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}